Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer is a PHASE2 clinical asset sponsored by UNC Lineberger Comprehensive Cancer Center in Bladder Cancer. SEO and diligence focus: Pembrolizumab, Entinostat, Procedure/Surgery, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.